Sian Bigora - 30 Apr 2026 Form 4/A - Amendment Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Chief Development Officer
Issuer ticker: PCSA
Reported as of: 30 Apr 2026
Net transaction value: +$5,341
SEC form: 4/A - Amendment
Accepted by SEC: 19 May 2026, 17:17:20 UTC
Original report date: 01 May 2026
Prior SEC filing: 17 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Sian Bigora by John J. Wolfel, as Attorney-in-Fact

Key filing fact

Sian Bigora filed Form 4/A - Amendment for Processa Pharmaceuticals, Inc. (PCSA) on 19 May 2026.

Key facts

This page summarizes Sian Bigora's Form 4/A - Amendment filing for Processa Pharmaceuticals, Inc. (PCSA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 17:17.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

CIK 0001799365 Primary reporting owner

Relationship: Chief Development Officer
Address: C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH
Signature: /s/ Sian Bigora by John J. Wolfel, as Attorney-in-Fact
Signature date: 19 May 2026

Shares, units, or other non-derivative securities reported in this filing.

PCSA transaction

Purchase

PCSA holding

No transaction description listed

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Section 16 status

Sian Bigora is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Shares adjusted to correct immaterial errors.